Key facts
- It has raised $40.3M.
- Notable investors include Connecticut Innovations, Innovestor, Business Finland, Tesi, Tekes — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Aurealis Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Aurealis Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Aurealis Therapeutics
Developer of a cell and gene therapy platform designed to heal multifactorial diseases. The company's platform facilitates a novel class of combination immunotherapy embedded in a single product that is efficient, scalable, and cost-effective, enabling medical professionals to get access to activate and modulate the innate immune system.
- Sector
- Healthcare
- HQ
- Zug, Switzerland
- Employees
- 18
- Website
- aurealistherapeutics.com/
- Ownership
- Privately Held (backing)
Aurealis Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Aurealis Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Aurealis Therapeutics in its N-PORT filings yet. We sweep new filings monthly.